Jun Shi

Jun Shi


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
YLYan Lu
Yan Lu
SLShulin/Sl Li
Shulin/Sl Li
SZShiguo Zhu
Shiguo Zhu
YGYa-bin Gong
Ya-bin Gong
JSJun Shi
Jun Shi
LXLing Xu
Ling Xu
DNA/RNA methylation plays an important role in lung cancer initiation and progression. Liquid biopsy makes use of cells, nucleotides and proteins released from tumor cells into body fluids to help with cancer diagnosis and prognosis. Methylation of circulating tumor DNA (ctDNA) has gained increasing attention as biomarkers for lung cancer. Here we briefly introduce the biological basis and detection method of ctDNA methylation, and review various applications of methylated DNA in body fluids in lung cancer screening, diagnosis, prognosis, monitoring and treatment prediction. We also discuss the emerging role of RNA methylation as biomarkers for cancer.

17 April 2015 in Oncology Reports
Verified
Journal Article
Open access
PDF file
JSJun Shi
Jun Shi
YLYong-Jin Li
Yong-Jin Li
BYBing Yan
Bing Yan
PWPin-Kang Wei
Pin-Kang Wei
Lymphatic metastasis is a major progression route of gastric cancer. Interleukin-8 (IL-8), as an inflammatory cytokine, is induced by Helicobacter pylori infection and is strongly associated with gastric cancer development and metastasis. The blood and lymphatic systems are similar in their function and gene expression profiles. It has been proposed that IL-8 activates angiogenesis. However, the direct role of IL-8 in lymphangiogenesis in gastric cancer remains unclear. We investigated the effect of IL-8 on the growth of human lymphatic endothelial cells (LECs). In addition, protein and mRNA expression of selected lymphangiogenesis markers was assessed in these cells. LECs were co-cultured with gastric cancer SGC7901 cells and exposed to various concentrations of IL-8 (0, 0.2, 0.5, 0.8 and 1.0 ng/ml). The Cell Counting Kit-8 was used to evaluate LEC proliferation (cultured for 1-6 days). Then, protein (immunofluorescence and western blotting) and mRNA [quantitative transcription-polymerase chain reaction (qPCR)] levels were measured in samples obtained from the 24-h cultured cells, for lymphatic vessel endothelial hyaluronic acid receptor-1 (LYVE-1), vascular endothelial growth factor (VEGF)-C, VEGF-D and vascular endothelial growth factor receptor-3 (VEGFR-3). The data presented herein demonstrated that IL-8 promotes the proliferation of LECs and enhances the protein and mRNA expression of LYVE-1. Notably, IL-8 inhibited VEGF-C, VEGF-D and VEGFR-3 protein expression as well as VEGF-D and VEGFR-3 mRNA expression. These findings suggest that IL-8 may be a potent inducer of LECs, although this effect does not appear to involve the VEGF-C/VEGF-D and VEGFR-3 signaling pathway.


18 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
QLQuan-Yao Li
Quan-Yao Li
FCFei-Hong Cai
Fei-Hong Cai
YLYing Lu
Ying Lu
HLHui Liu
Hui Liu
XWXiao Wang
Xiao Wang
JSJun Shi
Jun Shi
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse reaction of chemotherapy. Many studies have confirmed that traditional Chinese medicine (TCM) has unique advantages for treating CIPN. However, there is no standard TCM prescription in clinical practice or objective outcome index, and similar efficacy varies. Therefore, in this study, a systematic review of randomized controlled trials (RCTs) was performed to evaluate the clinical efficacy of external treatment with Chinese herbal medicine (CHM) for CIPN. This analysis provides evidence-based medical support for the use of CHM for external treatment of CIPN.Methods: Relevant RCTs assessing CHM external treatment of CIPN were searched in nine electronic databases, including the China National Knowledge Infrastructure Database, China Biology Medicine Disc, China Science and Technology Journal Database, Wanfang Database, PubMed, Cochrane Library, MEDLINE, Web of Science, and OVID, from inception to July 2021. A meta-analysis was performed on these studies using RevMan5.3 software.Results: Based on the inclusion and exclusion criteria, 33 clinical studies were included, while 1,354 studies were screened out. There were 2,356 patients in total, including 1,208 in the treatment group and 1,148 in the control group. In the treatment group, peripheral neurotoxicity rate, total effect rate, KPS score, TCM syndrome score and efficacy, pain NRS score, and pain relief rate were significantly improved compared with those of the control group (p < 0.01). Furthermore, the peroneal and median nerve conduction velocities were also improved compared with those in the control group (p < 0.05). By creating a funnel plot for the incidence of peripheral neurotoxicity and the total effect rate, we showed that the left and right sides were symmetrical, and that the publication bias was low.Conclusion: CHM external treatment was found to be an effective method for treating CIPN as it significantly improved clinical symptoms and quality of life in patients with CIPN.Clinical Trial Registration: identifier ChiCTR1900024617

3 November 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YLYing Lu
Ying Lu
QLQuan-Yao Li
Quan-Yao Li
LGLu Gan
Lu Gan
YYYi You
Yi You
CWChang-De Wang
Chang-De Wang
XLXiao-Ying Liu
Xiao-Ying Liu
Background: Migraine is a common disabling neurological disorder that affects the quality of human daily life and mental health, potentially leading to disability and imposing a substantial disease burden. There is currently a lack of literature analysis on the global burden and changing trends of migraines. Therefore, this study is of great significance for the development of effective management and prevention strategies for migraine by analyzing the global burden of migraine and its changing trends. Methods: We obtained data on the incidence, prevalence, and disability-adjusted life years (DALYs) of migraine by region and year from the Global Burden of Disease Study 2021 (GBD 2021). The estimated annual percentage change (EAPC) and 95% confidence interval (CI) were used to evaluate the time trend of disease burden, and factors that may affect the EAPC were analyzed. The burden of migraine was analyzed based on the Socio-demographic Index (SDI). Frontier analysis was used to visually demonstrate the burden of development levels in various regions, and the trends of migraine incidence, prevalence, and DALYs over the next decade were predicted. Results: In 2021, the global number of prevalent cases, incident cases, and DALYs for migraine were 1.158 billion, 90.18 million, and 43.38 million, compared with 1990, the percentage changes were 58, 42, and 58%, respectively. In 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALY rate (ASDR) of migraine were the highest in areas with high SDI. Its prevalence, incidence, and DALYs were 15365.1, 1222.5, and 573.6 per 100,000 people. From 1990 to 2021, the ASDR showed an upward trend globally and in all regions, among which ASIR and ASPR in global, China, East Asia, high, high-middle SDI regions were on the rise, while they showed a downward trend in low, low-middle SDI regions. Frontier analysis showed that areas with high SDI generally had greater potential for improvement. We used a predictive model to estimate that ASIR, ASPR, and ASDR of migraine were all on the rise. Conclusion: From 1990 to 2021, the global burden of migraine has increased significantly, especially in middle SDI region. This study highlights the importance of tailored interventions aimed at addressing migraine and thus contributing to the achievement of the Sustainable Development Goals set by the World Health Organization.

1 January 2023 in Integrative Cancer Therapies
Verified
Journal Article
Open access
QLQuanyao Li
Quanyao Li
WYWen-Xiao Yang
Wen-Xiao Yang
HLHui Liu
Hui Liu
LJLi-Jing Jiao
Li-Jing Jiao
YGYa-Bin Gong
Ya-Bin Gong
JSJun Shi
Jun Shi
Background: Cancer pain, a common complication of this disease, has been widely treated by electroacupuncture in recent years. However, there are numerous treatment parameters that are not conducive to clinical translation applications. This study aims to summarize the stimulation parameters commonly used in electroacupuncture treating cancer pain by data mining and visualization techniques to provide a basis for the future acupuncture technology transformation and selection of optimal stimulation parameters. Methods: Nine databases, including Pubmed, Cochrane Library, Embase, Web of Science, OVID, China National Knowledge Infrastructure Database, China Biology Medicine disk, China Science and Technology Journal Database, and Wanfang Database, were searched for clinical studies on electroacupuncture treatment cancer pain published between January 2012 and September 2022. A database was established using Microsoft Excel 2020 and analyzed with SPSS Modeler 18.1 software and SPSS statistics 26.0 software. Results: Twenty-four articles were included according to the established criteria. The most used electroacupuncture stimulation parameters were a dilatational wave, the current frequency of 2/100 Hz, stimulation duration of 30 minutes per treatment, and frequency of treatment once a day. Fifty-eight acupoints were mentioned, and the total frequency of acupoints involved was 156 times. The most used ones include Zusanli (ST36), Sanyinjiao (SP06), Hegu (LI04), Neiguan (PC06), Quchi (LI11), Taichong (LR03), Ashi point, Jiaji point, and those most generally used acupoints that are closely arranged on the Stomach Channel of Foot Yangming and the Spleen Channel of Foot Taiyin. The association analysis of acupoints revealed that the most supported acupoint pair was Sanyinjiao (SP06) and Zusanli (ST36). Cluster analysis demonstrated 3 groups, 1 for obligatory acupoints, 1 for Ashi point, and the third for Jiaji point. Conclusions: A dilatational wave, the current frequency of 2/100 Hz, 30-minute stimulation, and acupoints of the Stomach Channel of Foot Yangming and the Spleen Channel of Foot Taiyin selection are frequently used in electroacupuncture for treating cancer pain. Due to the limitations of this study, further research and more standardized, multi-center, large-sample clinical trials can be carried out to guide optimizing acupuncture treatment schemes and promote the formation of TCM-characteristic technologies for cancer pain.